An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated.
Dr Madish and colleagues assessed the long-term effect of H pylori eradication therapy on lymphocytic gastritis.
The investigative team conducted a double-blind, placebo-controlled, multicenter trial.
The team randomized 51 patients with lymphocytic gastritis to receive either 1-week triple therapy for eradication of H pylori or omeprazole plus placebo.
|96% were healed at 12 months after triple therapy vs 54% with omeprazole/placebo|
|Alimentary Pharmacology & Therapeutics|
Endoscopy and histology was performed at baseline and after 3 and 12 months.
Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy.
The team applied intention-to-treat analysis.
The investigators revealed that lymphocytic gastritis healing occurred in 83% at 3 months after triple therapy vs 58% with omeprazole/placebo.
After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy, at 96%, compared with omeprazole/placebo at 54%.
The team observed that all patients who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months.
Dr Madish's team commented, “Our study demonstrates that 1-week triple therapy aiming at eradication of H pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.”